Esmodoz-RD Capsule contains a combination of Domperidone 30mg and Esomeprazole 40mg, formulated to manage gastrointestinal disorders associated with acid reflux and delayed gastric emptying. Domperidone is a peripheral dopamine D2 receptor antagonist that enhances gastrointestinal motility by increasing the movement of the stomach and intestines, thereby facilitating gastric emptying and reducing symptoms such as nausea and vomiting. Esomeprazole, a proton pump inhibitor, selectively inhibits the H+/K+ ATPase enzyme system in gastric parietal cells, effectively suppressing gastric acid secretion and promoting mucosal healing in conditions like gastroesophageal reflux disease (GERD), erosive esophagitis, and Zollinger-Ellison syndrome. The synergistic effect of these two agents provides symptomatic relief from heartburn, acid regurgitation, and upper abdominal discomfort while improving gastric motility. Esmodoz-RD is indicated for patients with GERD accompanied by delayed gastric emptying or gastroparesis. It should be administered as prescribed by a healthcare professional, with attention to contraindications such as hypersensitivity to components, prolactin-dependent tumors, or significant cardiac arrhythmias. Caution is advised in patients with hepatic impairment or concomitant use of medications that prolong QT interval. Regular monitoring and adherence to recommended dosage enhance therapeutic outcomes and minimize adverse effects.